Do analysts prefer MGRX or AIDX?

20/20 Biolabs has a consensus target price of $5.00, indicating a potential upside of 745.31%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend BMGL or AIDX?

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 745.31%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than Basel Medical Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, BMGL or AIDX?

20/20 Biolabs has lower revenue, but higher earnings than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $14.55M 0.51 -$9.50M N/A N/A 20/20 Biolabs $2.05M 3.68 -$3.74M -$0.54 N/A

Is BMGL or AIDX more profitable?

Company Net Margins Return on Equity Return on Assets Basel Medical Group N/A N/A N/A 20/20 Biolabs N/A N/A N/A

Do analysts recommend GXAI or AIDX?

20/20 Biolabs has a consensus target price of $5.00, indicating a potential upside of 745.31%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than Gaxos.ai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is GXAI or AIDX more profitable?

20/20 Biolabs has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. 20/20 Biolabs' return on equity of 0.00% beat Gaxos.ai's return on equity. Company Net Margins Return on Equity Return on Assets Gaxos.ai -64.81% -38.79% -36.99% 20/20 Biolabs N/A N/A N/A

Do analysts rate AIDX or NIVF?

20/20 Biolabs currently has a consensus price target of $5.00, suggesting a potential upside of 745.31%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, equities research analysts plainly believe 20/20 Biolabs is more favorable than NewGenIvf Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, AIDX or NIVF?

NewGenIvf Group has higher revenue and earnings than 20/20 Biolabs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 20/20 Biolabs $2.05M 3.68 -$3.74M -$0.54 N/A NewGenIvf Group $4.73M 0.51 $9.88M N/A N/A

Is AIDX or NIVF more profitable?

Company Net Margins Return on Equity Return on Assets 20/20 Biolabs N/A N/A N/A NewGenIvf Group N/A N/A N/A

20/20 Biolabs (AIDX) Competitors

$0.59 -0.02 (-3.27%)

As of 09/4/2026 03:58 PM Eastern

Compare

AIDX vs. MGRX, BMGL, GXAI, NIVF, and IVF

Should you buy 20/20 Biolabs stock or one of its competitors? 20/20 Biolabs's main competitors and comparable companies include Mangoceuticals (MGRX), Basel Medical Group (BMGL), Gaxos.ai (GXAI), NewGenIvf Group (NIVF), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does 20/20 Biolabs compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

56.7% of Mangoceuticals shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by company insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

20/20 Biolabs has a consensus target price of $5.00, indicating a potential upside of 745.31%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Mangoceuticals' average media sentiment score of 0.00 equaled 20/20 Biolabs'average media sentiment score.

Company	Overall Sentiment
Mangoceuticals	Neutral
20/20 Biolabs	Neutral

20/20 Biolabs has higher revenue and earnings than Mangoceuticals. 20/20 Biolabs is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$315.23K	28.12	-$20.64M	-$1.01	N/A
20/20 Biolabs	$2.05M	3.68	-$3.74M	-$0.54	N/A

20/20 Biolabs has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. 20/20 Biolabs' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
20/20 Biolabs	N/A	N/A	N/A

Summary

20/20 Biolabs beats Mangoceuticals on 10 of the 13 factors compared between the two stocks.

How does 20/20 Biolabs compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 745.31%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than Basel Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Basel Medical Group had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 1 mentions for Basel Medical Group and 0 mentions for 20/20 Biolabs. Basel Medical Group's average media sentiment score of 1.14 beat 20/20 Biolabs' score of 0.00 indicating that Basel Medical Group is being referred to more favorably in the media.

Company	Overall Sentiment
Basel Medical Group	Positive
20/20 Biolabs	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
20/20 Biolabs	N/A	N/A	N/A

20/20 Biolabs has lower revenue, but higher earnings than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$14.55M	0.51	-$9.50M	N/A	N/A
20/20 Biolabs	$2.05M	3.68	-$3.74M	-$0.54	N/A

Summary

20/20 Biolabs beats Basel Medical Group on 5 of the 8 factors compared between the two stocks.

How does 20/20 Biolabs compare to Gaxos.ai?

Gaxos.ai (NASDAQ:GXAI) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Gaxos.ai's average media sentiment score of 0.00 equaled 20/20 Biolabs'average media sentiment score.

Company	Overall Sentiment
Gaxos.ai	Neutral
20/20 Biolabs	Neutral

20/20 Biolabs has a consensus target price of $5.00, indicating a potential upside of 745.31%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than Gaxos.ai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

20/20 Biolabs has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. 20/20 Biolabs' return on equity of 0.00% beat Gaxos.ai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gaxos.ai	-64.81%	-38.79%	-36.99%
20/20 Biolabs	N/A	N/A	N/A

20/20 Biolabs has higher revenue and earnings than Gaxos.ai. Gaxos.ai is trading at a lower price-to-earnings ratio than 20/20 Biolabs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gaxos.ai	$1.93M	2.79	-$3.90M	-$0.50	N/A
20/20 Biolabs	$2.05M	3.68	-$3.74M	-$0.54	N/A

42.6% of Gaxos.ai shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by company insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

20/20 Biolabs beats Gaxos.ai on 11 of the 13 factors compared between the two stocks.

How does 20/20 Biolabs compare to NewGenIvf Group?

20/20 Biolabs (NASDAQ:AIDX) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
NewGenIvf Group	N/A	N/A	N/A

NewGenIvf Group has higher revenue and earnings than 20/20 Biolabs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	3.68	-$3.74M	-$0.54	N/A
NewGenIvf Group	$4.73M	0.51	$9.88M	N/A	N/A

20/20 Biolabs currently has a consensus price target of $5.00, suggesting a potential upside of 745.31%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, equities research analysts plainly believe 20/20 Biolabs is more favorable than NewGenIvf Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

66.2% of NewGenIvf Group shares are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by insiders. Comparatively, 31.8% of NewGenIvf Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, NewGenIvf Group had 7 more articles in the media than 20/20 Biolabs. MarketBeat recorded 7 mentions for NewGenIvf Group and 0 mentions for 20/20 Biolabs. NewGenIvf Group's average media sentiment score of 1.51 beat 20/20 Biolabs' score of 0.00 indicating that NewGenIvf Group is being referred to more favorably in the news media.

Company	Overall Sentiment
20/20 Biolabs	Neutral
NewGenIvf Group	Very Positive

Summary

NewGenIvf Group beats 20/20 Biolabs on 6 of the 10 factors compared between the two stocks.

How does 20/20 Biolabs compare to INVO Fertility?

20/20 Biolabs (NASDAQ:AIDX) and INVO Fertility (NASDAQ:IVF) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

20/20 Biolabs presently has a consensus target price of $5.00, indicating a potential upside of 745.31%. INVO Fertility has a consensus target price of $20.00, indicating a potential upside of 1,930.46%. Given INVO Fertility's stronger consensus rating and higher probable upside, analysts plainly believe INVO Fertility is more favorable than 20/20 Biolabs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, INVO Fertility had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 1 mentions for INVO Fertility and 0 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 0.00 equaled INVO Fertility'saverage media sentiment score.

Company	Overall Sentiment
20/20 Biolabs	Neutral
INVO Fertility	Neutral

12.0% of INVO Fertility shares are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by insiders. Comparatively, 0.4% of INVO Fertility shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

20/20 Biolabs has higher earnings, but lower revenue than INVO Fertility. 20/20 Biolabs is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	3.68	-$3.74M	-$0.54	N/A
INVO Fertility	$6.84M	0.36	-$25.13M	-$33.83	N/A

20/20 Biolabs has a net margin of 0.00% compared to INVO Fertility's net margin of -116.29%. 20/20 Biolabs' return on equity of 0.00% beat INVO Fertility's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
INVO Fertility	-116.29%	-85.54%	-31.05%

Summary

20/20 Biolabs beats INVO Fertility on 8 of the 15 factors compared between the two stocks.

Get 20/20 Biolabs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIDX vs. The Competition

Export

Metric	20/20 Biolabs	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.55M	$10.00B	$7.25B	$12.91B
Dividend Yield	N/A	2.59%	2.53%	9.14%
P/E Ratio	-1.10	34.60	274.10	25.45
Price / Sales	3.68	5.71	687.94	125.94
Price / Cash	N/A	121.42	77.08	52.44
Price / Book	4.55	3.99	12.85	6.17
Net Income	-$3.74M	$313.25M	$3.49B	$350.08M
7 Day Performance	-5.21%	1.06%	1.04%	-0.14%
1 Month Performance	30.89%	1.22%	5.39%	0.94%
1 Year Performance	N/A	15.34%	24.18%	14.02%

20/20 Biolabs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIDX 20/20 Biolabs	2.062 of 5 stars	$0.59 -3.3%	$5.00 +745.3%	N/A	$7.55M	$2.05M	N/A	14	Gap Down
MGRX Mangoceuticals	0.4738 of 5 stars	$0.37 -11.8%	N/A	-81.4%	$8.05M	$460K	N/A	3	Positive News Gap Down
BMGL Basel Medical Group	0.9608 of 5 stars	$4.93 -7.1%	N/A	-80.3%	$7.68M	$8.90M	N/A	36	Gap Down
GXAI Gaxos.ai	0.3141 of 5 stars	$0.86 -1.8%	N/A	-51.6%	$6.15M	$6.01M	N/A	3
NIVF NewGenIvf Group	2.6209 of 5 stars	$0.51 -12.1%	N/A	-99.9%	$3.03M	$4.73M	N/A	N/A	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIDX) was last updated on 9/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

20/20 Biolabs (AIDX) Competitors

AIDX vs. MGRX, BMGL, GXAI, NIVF, and IVF

How does 20/20 Biolabs compare to Mangoceuticals?

Summary

How does 20/20 Biolabs compare to Basel Medical Group?

Summary

How does 20/20 Biolabs compare to Gaxos.ai?

Summary

How does 20/20 Biolabs compare to NewGenIvf Group?

Summary

How does 20/20 Biolabs compare to INVO Fertility?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

20/20 Biolabs (AIDX) Competitors

AIDX vs. MGRX, BMGL, GXAI, NIVF, and IVF

How does 20/20 Biolabs compare to Mangoceuticals?

Do insiders & institutionals believe in MGRX or AIDX?

Do analysts prefer MGRX or AIDX?

Does the media favor MGRX or AIDX?

Which has better earnings and valuation, MGRX or AIDX?

Is MGRX or AIDX more profitable?

Summary

How does 20/20 Biolabs compare to Basel Medical Group?

Do analysts recommend BMGL or AIDX?

Does the media favor BMGL or AIDX?

Is BMGL or AIDX more profitable?

Which has better valuation & earnings, BMGL or AIDX?

Summary

How does 20/20 Biolabs compare to Gaxos.ai?

Does the media refer more to GXAI or AIDX?

Do analysts recommend GXAI or AIDX?

Is GXAI or AIDX more profitable?

Which has higher earnings and valuation, GXAI or AIDX?

Do insiders & institutionals believe in GXAI or AIDX?

Summary

How does 20/20 Biolabs compare to NewGenIvf Group?

Is AIDX or NIVF more profitable?

Which has preferable valuation & earnings, AIDX or NIVF?

Do analysts rate AIDX or NIVF?

Do insiders and institutionals believe in AIDX or NIVF?

Does the media favor AIDX or NIVF?

Summary

How does 20/20 Biolabs compare to INVO Fertility?

Do analysts rate AIDX or IVF?

Does the media refer more to AIDX or IVF?

Do institutionals & insiders believe in AIDX or IVF?

Which has better valuation and earnings, AIDX or IVF?

Is AIDX or IVF more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools